MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2025
0mins
Source: Globenewswire
MeiraGTx Presentations at ASGCT 2025: MeiraGTx Holdings announced four poster presentations at the American Society of Gene and Cell Therapy Annual Meeting, showcasing advancements in gene therapies for severe pediatric obesity, optimized promoters for gene expression, and preclinical efficacy of AAV-hUPF1 for ALS and Frontotemporal Dementia.
Innovative Gene Therapy Developments: The company highlighted significant findings, including a potent AAV-BDNF vector that effectively reduces weight in obese mice, novel CAG-based promoters that enhance gene therapy safety, and the potential of AAV-hUPF1 to treat neurodegenerative diseases by improving motor neuron survival.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
